Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort – EPICOV - Warszawski, Josiane; Meyer, Laurence; Franck, Jeanna-Eve; Rahib, Delphine; Lydié, Nathalie; Gosselin, Anne; Counil, Emilie; Kreling, Robin; Novelli, Sophie; Slama, Remy; Raynaud, Philippe; Bagein, Guillaume; et al. (medRxiv, 2021)
Background We aimed to study whether social patterns of exposure to SARS-CoV-2 infection changed in France throughout the year 2020, in light to the easing of social contact restrictions.Methods A population-based cohort of individuals aged 15 years or over was randomly selected from the national tax register to collect socio-economic data, migration history, and living conditions in May and November 2020. Home self-sampling on dried blood was proposed to a 10% random subsample in May and to all in November. A positive anti-SARS-CoV-2 ELISA IgG result against the virus spike protein (ELISA-S) was the primary outcome. The design, including sampling and post-stratification weights, was taken into account in univariate and multivariate analyses.Results Of the 134,391 participants in May, 107,759 completed the second questionnaire in November, and respectively 12,114 and 63,524 were tested. The national ELISA-S seroprevalence was 4.5% [95%CI: 4.0%-5.1%] in May and 6.2% [5.9%-6.6%] in November. It increased markedly in 18-24-year-old population from 4.8% to 10.0%, and among second-generation immigrants from outside Europe from 5.9% to 14.4%. This group remained strongly associated with seropositivity in November, after controlling for any contextual or individual variables, with an adjusted OR of 2.1 [1.7-2.7], compared to the majority population. In both periods, seroprevalence remained higher in healthcare professions than in other occupations.Conclusion The risk of Covid-19 infection increased among young people and second-generation migrants between the first and second epidemic waves, in a context of less strict social restrictions, which seems to have reinforced territorialized socialization among peers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by research grants from Inserm Institut National de la Sante et de la Recherche Medicale and the French Ministry for Research, by Drees Direction de la Recherche, Etudes, Evaluation et Statistiques, and the French Ministry for Health, and by the Region Ile de France. Dr Bajos has received funding from the European Research Council ERC under the European Horizon 2020 research and innovation programme (grant agreement No 856478) This project has also received funding from the European Horizon 2020 research and innovation programme under grant agreement No 101016167, ORCHESTRA Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The French data protection authority CNIL (MLD/MFI/AR205138, on April 25th, 2020, last revised on October 2nd 2020), the ethics IRB Comite de Protection des Personnes Sud Meediterranee III (2020-A01191-38, on April 25th 2020, last revised on September 2nd, 2020), and the Comite du Label de la Statistique Publique gave approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymous aggregated data for the first round are available online. The EpiCov dataset is available for research purpose concerning the first round, and will be available by March 2022 concerning the second round for research purpose on CASD (https://www.casd.eu/), after submission to approval of French Ethics and Regulatory Committee procedure (Comite du Secret Statistique, CESREES and CNIL). Access to anonymized individual data underlying the findings may be available before the planned period, on request to the corresponding author, to be submitted to approval of ethics and reglementary Committee for researchers who meet the criteria for access to data.